This clinical trial is to clarify whether treatment with a checkpoint inhibitor alone
(pembrolizumab) or two in combination (ipilimumab and nivolumab), results in clinical benefit
for MM patients with brain metastases and in need of steroid treatment. Patients will be
treated in four arms depending on steroid dose level at inclusion (> 10 < 25 mg prednisolone
or > 25 mg prednisolone) and treatment (pembrolizumab alone or the combination of ipilimumab
and nivolumab).